Claims
- 1. A synthetic particulate vector comprising a non-liquid hydrophilic core, wherein said vector does not have an external lipid layer grafted thereon.
- 2. The synthetic particulate vector according to claim 1, wherein the hydrophilic core comprises a matrix of polysaccharides or oligosaccharides which are naturally or chemically crosslinked.
- 3. The synthetic particulate vector according to claim 1, wherein ionic ligands are grafted onto the hydrophilic core.
- 4. The synthetic particulate vector according to claim 1, further comprising an active principle.
- 5. The synthetic particulate vector according to claim 4, wherein the active principle is an ionizable molecule localized mainly at the center of the matrix.
- 6. The synthetic particulate vector according to claim 1, wherein said vector has a diameter of between 10 nm and 5 μm.
- 7. The synthetic particulate vector according to claim 6, wherein said vector has a diameter of between 20 and 200 nm.
- 8. The synthetic particulate vector according to claim 4, wherein said active principle is selected from the group consisting of antibiotics, antiviral agents, proteins, proteoglycans, peptides, polysaccharides, lipopolysaccharides, antibodies, antigens, insecticides, fungicides, compounds which act on the cardiovascular system, anticancer agents, antimalarial agents, antiasthmatic agents, compounds having an effect on the skin, and constituents of dairy fat globules.
- 9. A process for preparing a particulate vector according to claim 4, wherein the vector is charged with an active principle, said process comprising:
(a) preparing the particulate vector comprising a non-liquid hydrophilic matrix on which are fixed ionic ligands; (b) suspending the particulate vector in a solution at a pH at which the active principle is weakly ionized; (c) adding the active principle to the suspension of (b) while supplying energy; (d) recovering from the solution the particulate vector which is charged with active principle.
- 10. A process for preparing a particulate vector according to claim 4, said method comprising:
(a) encapsulating an acidic or basic ionizable active principle in a crosslinked hydrophilic matrix grafted by ligands of an ionic species of opposite ionic charge with that of the active principle, at a pH at which the active principle is in the ionized form; (b) varying the pH of the medium, with respect to the pKa of the active principle, to a value at which the active principle is not in an ionized form; and (c) recovering the hydrophilic matrix which comprises the active principle localized mainly at the center of said matrix.
- 11. The process for preparing a particulate vector according to claim 10, comprising:
(a) encapsulating a basic ionizable active principle in a crosslinked hydrophilic matrix grafted by acidic ionic ligands, at a pH below the pKa of the active principle; and (b) increasing the pH of the medium to a value above the pKa of the active principle.
- 12. The process for preparing a particulate vector according to claim 10, comprising:
(a) encapsulating an acidic ionizable active principle in a crosslinked hydrophilic matrix grafted by basic ionic ligands, at a pH above the pKa of the active principle; and (b) decreasing the pH of the medium to a value below the pKa of the active principle.
- 13. The process for preparing a particulate vector according to claim 10, wherein the hydrophilic matrix comprises polysaccharides or oligosaccharides which are naturally or chemically crosslinked.
- 14. A pharmaceutical composition of matter comprising a particulate vector according to claim 1, and a pharmaceutically acceptable support for administration thereof.
- 15. A cosmetological composition comprising a particulate vector according to claim 1, and cosmetologically acceptable excipients therefor.
- 16. A process for preparing a pharmaceutical composition comprising encapsulating an acidic or basic ionizable active principle in a particulate vector according to claim 1.
- 17. A method of treating a medical condition comprising administering a vector according to claim 1 to a patient in need of such treatment.
- 18. A synthetic particulate vector consisting essentially of a non-liquid hydrophilic matrix.
- 19. The synthetic particulate vector according to claim 18, wherein the hydrophilic core comprises a matrix of polysaccharides or oligosaccharides which are naturally or chemically crosslinked.
- 20. The synthetic particulate vector according to claim 18, wherein ionic ligands are grafted onto the hydrophilic core.
- 21. The synthetic particulate vector according to claim 18, further comprising an active principle.
- 22. The synthetic particulate vector according to claim 21, wherein the active principle is an ionizable molecule localized mainly at the center of the matrix.
- 23. The synthetic particulate vector according to claim 18, wherein said vector has a diameter of between 10 nm and 5 μm.
- 24. The synthetic particulate vector according to claim 23, wherein said vector has a diameter of between 20 and 200 nm.
- 25. The synthetic particulate vector according to claim 21, wherein said active principle is selected from the group consisting of antibiotics, antiviral agents, proteins, proteoglycans, peptides, polysaccharides, lipopolysaccharides, antibodies, antigens, insecticides, fungicides, compounds which act on the cardiovascular system, anticancer agents, antimalarial agents, antiasthmatic agents, compounds having an effect on the skin, and constituents of dairy fat globules.
Priority Claims (2)
Number |
Date |
Country |
Kind |
PCTFR9400228 |
Mar 1994 |
WO |
|
93 02397 |
Mar 1993 |
FR |
|
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation in part of U.S. application Ser. No. 08/513,853, filed May 1, 1996. Application Ser. No. 08/513,853 is incorporated by reference in its entirety.
Continuations (1)
|
Number |
Date |
Country |
Parent |
08513853 |
May 1996 |
US |
Child |
09112367 |
Jul 1998 |
US |